KORU Medical Systems (NASDAQ:KRMD - Get Free Report)'s stock had its "neutral" rating restated by equities researchers at Piper Sandler in a research note issued on Friday, Marketbeat reports. They presently have a $4.50 target price on the stock. Piper Sandler's target price would suggest a potential upside of 8.43% from the stock's current price.
A number of other equities analysts have also commented on KRMD. Lake Street Capital boosted their price objective on shares of KORU Medical Systems from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday, January 14th. Craig Hallum upped their target price on shares of KORU Medical Systems from $5.00 to $6.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Finally, Canaccord Genuity Group upped their target price on shares of KORU Medical Systems from $3.00 to $4.00 and gave the company a "buy" rating in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $4.70.
View Our Latest Stock Report on KRMD
KORU Medical Systems Stock Down 5.0 %
KRMD stock traded down $0.22 during trading on Friday, reaching $4.15. The stock had a trading volume of 189,183 shares, compared to its average volume of 224,403. KORU Medical Systems has a 1-year low of $2.01 and a 1-year high of $5.05. The company has a current ratio of 2.99, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $190.24 million, a P/E ratio of -16.60 and a beta of 0.45. The firm has a fifty day moving average price of $4.16 and a 200 day moving average price of $3.26.
Institutional Investors Weigh In On KORU Medical Systems
Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in KORU Medical Systems during the third quarter worth about $34,000. JPMorgan Chase & Co. raised its stake in KORU Medical Systems by 2,770.7% during the fourth quarter. JPMorgan Chase & Co. now owns 17,712 shares of the company's stock worth $68,000 after acquiring an additional 17,095 shares during the period. Virtu Financial LLC acquired a new stake in KORU Medical Systems during the fourth quarter worth about $73,000. Vivaldi Capital Management LP acquired a new stake in KORU Medical Systems during the fourth quarter worth about $82,000. Finally, Balyasny Asset Management L.P. acquired a new stake in KORU Medical Systems during the fourth quarter worth about $84,000. Institutional investors and hedge funds own 58.60% of the company's stock.
KORU Medical Systems Company Profile
(
Get Free Report)
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.
Featured Articles

Before you consider KORU Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KORU Medical Systems wasn't on the list.
While KORU Medical Systems currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.